Sodium–glucose cotransporter 2 inhibitors and the cancer patient: from diabetes to cardioprotection and beyond
Basic Research in Cardiology · 27.06.2024 · 120 (1) · 241-262
DOI: 10.1007/s00395-024-01059-9 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Basic Research in Cardiology, online erschienen am 27.06.2024. Verfasst von Massimiliano Camilli und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart, Rome, Italy. Massimiliano.camilli1@policlinicogemelli.i…. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Neoplasms, Cardiotonic Agents, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 171 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università Cattolica del Sacro Cuore.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Sodium–glucose cotransporter 2 inhibitors (SGLT2i), a new drug class initially designed and approved for treatment of diabetes mellitus, have been shown to exert pleiotropic metabolic and direct cardioprotective and nephroprotective effects that extend beyond their glucose-lowering action. These properties prompted their use in two frequently intertwined conditions, heart failure and chronic kidney disease. Their unique mechanism of action makes SGLT2i an attractive option also to lower the rate of cardiac events and improve overall survival of oncological patients with preexisting cardiovascular risk and/or candidate to receive cardiotoxic therapies. This review will cover biological foundations and clinical evidence for SGLT2i modulating myocardial function and metabolism, with a focus on their possible use as cardioprotective agents in the cardio-oncology settings. Furthermore, we will explore recently emerged SGLT2i effects on hematopoiesis and immune system, carrying the potential of attenuating tumor growth and chemotherapy-induced cytopenias.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart, Rome, Italy. Massimiliano.camilli1@policlinicogemelli.it.
- Department of Cardiovascular Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, L.go A. Gemelli, 1, 00168, Rome, Italy. Massimiliano.camilli1@policlinicogemelli.it.
- Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Rome, Italy.
- Department of Cardiovascular Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, L.go A. Gemelli, 1, 00168, Rome, Italy.
- Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart, Rome, Italy.
- Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Förderung
- Università Cattolica del Sacro Cuore
Zitieren
APA
Camilli, M., Viscovo, M., Maggio, L., Bonanni, A., Torre, I., Pellegrino, C., Lamendola, P., Tinti, L., Teofili, L., Hohaus, S., Lanza, G. A., Ferdinandy, P., Varga, Z., Crea, F., Lombardo, A., & Minotti, G. (2024). Sodium–glucose cotransporter 2 inhibitors and the cancer patient: from diabetes to cardioprotection and beyond. Basic Research in Cardiology, 120(1), 241-262. https://doi.org/10.1007/s00395-024-01059-9
Vancouver
Camilli M, Viscovo M, Maggio L, Bonanni A, Torre I, Pellegrino C, et al. Sodium–glucose cotransporter 2 inhibitors and the cancer patient: from diabetes to cardioprotection and beyond. Basic Research in Cardiology. 2024;120(1):241-262. doi:10.1007/s00395-024-01059-9
BibTeX
@article{Camilli2024,
author = {Camilli, Massimiliano and Viscovo, Marcello and Maggio, Luca and Bonanni, Alice and Torre, Ilaria and Pellegrino, Claudio and Lamendola, Priscilla and Tinti, Lorenzo and Teofili, Luciana and Hohaus, Stefan and Lanza, Gaetano Antonio and Ferdinandy, Peter and Varga, Zoltan and Crea, Filippo and Lombardo, Antonella and Minotti, Giorgio},
title = {Sodium–glucose cotransporter 2 inhibitors and the cancer patient: from diabetes to cardioprotection and beyond},
journal = {Basic Research in Cardiology},
year = {2024},
volume = {120},
number = {1},
pages = {241--262},
doi = {10.1007/s00395-024-01059-9}
}
EUVIMED